For the Inventor, By the Inventor

Enter assignee name

Newark, CA, United States of America

Revance Therapeutics, Inc.

USPTO Granted Patents = 34

% Expired Patents = 17.6

CIPO Patents = 3

EPO Patents = 16

Trademarks = 20

Forward Citations = 253

Loading Chart...

Loading Chart...

9 inventors (with patents filed for the assignee):

Jacob M Waugh (26 out of 34 patents)

Michael D Dake (12 out of 34 patents)

Curtis L Ruegg (11 out of 19 patents)

4. Gary E Borodic (5 out of 31 patents)

5. Stewart A Thompson (4 out of 7 patents)

6. Hongran Fan Stone (4 out of 4 patents)

7. Martin Andrew Acquadro (1 out of 7 patents)

8. Jae Hoon Lee (1 out of 1 patent)

9. Sunita Babbar (1 out of 1 patent)

10. Alice Du (0 patent)

11. Hongran Fan Stone (0 patent)

12. Connie L Ho (0 patent)

13. Dan Browne (0 patent)

14. Hongran F Stone (0 patent)

Core Competencies:

Cervical Dystonia

Botulinum Toxin

Transdermal Delivery

Ocular Surface Disease

Pain Treatment

Albumin-Free Formulations

Topical Application

Transmucosal Compositions

Neurotoxin Purification

Mood Disorders

Acne Treatment

Biological Transport Systems

34 patents: Sort by Forward Citations

1. 12257293 - Methods of treatment for cervical dystonia (2025-03-25),

2. 12161703 - Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders (2024-12-10),

3. 11911449 - Albumin-free botulinum toxin formulations (2024-02-27),

4. 11484580 - Topical ocular preparation of botulinum toxin for use in ocular surface disease (2022-11-01),

5. 11471708 - Injectable botulinum toxin formulations (2022-10-18),

6. 11466262 - Methods and systems for purifying non-complexedneurotoxin (2022-10-11),

7. 11351232 - Albumin-free botulinum toxin formulations (2022-06-07),

8. 10857215 - Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds (2020-12-08),

9. 10744078 - Compositions and methods for topical application and transdermal delivery of botulinum toxins (2020-08-18),

10. 10441641 - Botulinum toxin and the treatment of primary disorders of mood and affect (2019-10-15),

11. 10201594 - Compositions and methods for safe treatment of rhinitis (2019-02-12),

12. 10172877 - Compositions and methods for topical diagnostic and therapeutic transport (2019-01-08),

13. 10111939 - Albumin-free botulinum toxin formulations (2018-10-30),

14. 10080786 - Methods for treating pain by topical application and transdermal delivery of botulinum toxin (2018-09-25),

15. 9956435 - Injectable botulinum toxin formulations (2018-05-01),

Revance Therapeutics, Inc. is a biotechnology company based in Newark, California, focused on innovative aesthetic and therapeutic offerings. The company specializes in the development of advanced neuromodulators and dermal fillers, leveraging its proprietary DaxibotulinumtoxinA technology. Revance aims to enhance patient outcomes through its research in the fields of aesthetics and therapeutics, with a commitment to delivering transformative solutions that address unmet medical needs.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Revance Therapeutics, Inc.

34 Patents

#16 in Newark, CA

#2,377 in California

#10,002 in US

#19,612 in the World

Newark, CA, United States of America

Revance Therapeutics, Inc.

Forward Citations = 253

9 inventors:

Jacob M Waugh (26 out of 34 patents)

Michael D Dake (12 out of 34 patents)

Curtis L Ruegg (11 out of 19 patents)

4. Gary E Borodic (5 out of 31 patents)

5. Stewart A Thompson (4 out of 7 patents)

Please report any incorrect information to [email protected]

Loading…